Amgen (XSGO:AMGN) Other Long Term Assets : $9,007 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Amgen Other Long Term Assets?

Amgen's other long-term assets for the quarter that ended in Mar. 2024 was $9,007 Mil.

Amgen's quarterly other long-term assets increased from Sep. 2023 ($7,835 Mil) to Dec. 2023 ($9,611 Mil) but then stayed the same from Dec. 2023 ($9,611 Mil) to Mar. 2024 ($9,007 Mil).

Amgen's annual other long-term assets declined from Dec. 2021 ($6,524 Mil) to Dec. 2022 ($5,899 Mil) but then increased from Dec. 2022 ($5,899 Mil) to Dec. 2023 ($9,611 Mil).

Amgen Other Long Term Assets Historical Data

The historical data trend for Amgen's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Other Long Term Assets Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

2,223.00

5,639.00

6,524.00

5,899.00

9,611.00

Amgen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long Term Assets	Get a 7-Day Free Trial															7,633.00	7,193.00	7,835.00	9,611.00	9,007.00

Amgen Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Amgen (XSGO:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (XSGO:AMGN) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMG:Germany AMG:Germany AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.